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Abstract: Background: Chronic obstructive pulmonary disease (COPD) is one of the most common dis-
orders in the world. COPD is characterized by airflow obstruction, which is not fully reversible. Patients
usually experience breathing-related symptoms with periods of acute worsening and a substantial decrease
in the health-related quality-of-life. Active and comprehensive disease management can slow down the
progressive course of the disease and improve patients’ disabilities. Technological progress and digitaliza-
tion of medicine have the potential to make elaborate interventions easily accessible and applicable to a
broad spectrum of patients with COPD without increasing the costs of the intervention. Objective: This
study aims to develop a comprehensive telemonitoring and hybrid virtual coaching solution and to inves-
tigate its effects on the health-related quality of life of patients with COPD. Methods: A monocentric,
assessor-blind, two-arm (intervention/control) randomized controlled trial will be performed. Partic-
ipants randomized to the control group will receive usual care and a CAir Desk (custom-built home
disease-monitoring device to telemonitor disease-relevant parameters) for 12 weeks, without feedback or
scores of the telemonitoring efforts and virtual coaching. Participants randomized to the intervention
group will receive a CAir Desk and a hybrid digital coaching intervention for 12 weeks. As a primary
outcome, we will measure the delta in the health-related quality of life, which we will assess with the
St. George Respiratory Questionnaire, from baseline to week 12 (the end of the intervention). Results:
The development of the CAir Desk and virtual coach has been completed. Recruitment to the trial
started in September 2020. We expect to start data collection by December 2020 and expect it to last for
approximately 18 months, as we follow a multiwave approach. We expect to complete data collection by
mid-2022 and plan the dissemination of the results subsequently. Conclusions: To our knowledge, this
is the first study investigating a combination of telemonitoring and hybrid virtual coaching in patients
with COPD. We will investigate the effectiveness, efficacy, and usability of the proposed intervention and
provide evidence to further develop app-based and chatbot-based disease monitoring and interventions
in COPD.
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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is one of the most common disorders in the world. COPD is
characterized by airflow obstruction, which is not fully reversible. Patients usually experience breathing-related symptoms with
periods of acute worsening and a substantial decrease in the health-related quality-of-life. Active and comprehensive disease
management can slow down the progressive course of the disease and improve patients’ disabilities. Technological progress and
digitalization of medicine have the potential to make elaborate interventions easily accessible and applicable to a broad spectrum
of patients with COPD without increasing the costs of the intervention.
Objective: This study aims to develop a comprehensive telemonitoring and hybrid virtual coaching solution and to investigate
its effects on the health-related quality of life of patients with COPD.
Methods: A monocentric, assessor-blind, two-arm (intervention/control) randomized controlled trial will be performed.
Participants randomized to the control group will receive usual care and a CAir Desk (custom-built home disease-monitoring
device to telemonitor disease-relevant parameters) for 12 weeks, without feedback or scores of the telemonitoring efforts and
virtual coaching. Participants randomized to the intervention group will receive a CAir Desk and a hybrid digital coaching
intervention for 12 weeks. As a primary outcome, we will measure the delta in the health-related quality of life, which we will
assess with the St. George Respiratory Questionnaire, from baseline to week 12 (the end of the intervention).
Results: The development of the CAir Desk and virtual coach has been completed. Recruitment to the trial started in September
2020. We expect to start data collection by December 2020 and expect it to last for approximately 18 months, as we follow a
multiwave approach. We expect to complete data collection by mid-2022 and plan the dissemination of the results subsequently.
Conclusions: To our knowledge, this is the first study investigating a combination of telemonitoring and hybrid virtual coaching
in patients with COPD. We will investigate the effectiveness, efficacy, and usability of the proposed intervention and provide
evidence to further develop app-based and chatbot-based disease monitoring and interventions in COPD.
Trial Registration: ClinicalTrials.gov identifier: NCT04373070; https://clinicaltrials.gov/ct2/show/NCT04373070
International Registered Report Identifier (IRRID): DERR1-10.2196/20412
(JMIR Res Protoc 2020;9(10):e20412) doi: 10.2196/20412
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Chronic obstructive pulmonary disease (COPD) is a chronic
lung disease commonly caused by exposure to noxious particles
(primarily from smoking) and characterized by respiratory
symptoms (ie, dyspnea, cough, and sputum) and airflow
obstruction [1]. Patients experience persistent respiratory
symptoms with periods of acute worsening (exacerbations) and
a substantial decrease in health-related quality of life (HRQOL).
In 2016, about 251 million people worldwide were affected by
COPD [2]. COPD is projected to become the third-leading
global cause of death by 2030 [3]. In addition to the health
implications, COPD causes a substantial economic burden on
the individual and the health care systems [4]. There is no cure
for COPD. However, effective treatment such as medication,
smoking cessation, and physical exercise helps to relieve
symptoms and prevent exacerbations [5]. Active disease
management to reduce the burden of COPD and improve
HRQOL therefore plays a crucial role in the therapeutic strategy.
Effective COPD management plans follow a patient-centered
approach and aim to (1) prevent disease progression through
the reduction of risk factors, (2) improve exercise tolerance, (3)
improve health status, and (4) relieve symptoms [5]. Best
practice treatment of COPD should be multidimensional and
include medical care, self-management strategies, physical
activity coaching, and behavioral change approaches [6-8]. One
of these evidence-based disease management programs is Living
well with COPD [9,10]. The program was developed by a
Canadian consortium and is based on a disease self-management
approach that covers educational topics as well as lifestyle
coaching and physical activity advice supervised by health care
professionals [9]. A randomized clinical trial showed that
compared to usual care in a multicenter setup, the Living well
with COPD intervention program reduced hospital admissions
due to COPD exacerbations, emergency department visits, and
unscheduled physician visits and improved HRQOL
significantly [9]. A recent clinical trial conducted in Switzerland
confirmed these results [8]. The implementation of the program,
however, is both time and cost intensive.
Technological progress and the digitalization of medicine have
the potential to make comprehensive interventions such as the
Living well with COPD program easily accessible and applicable
to a broad spectrum of patients with COPD without increasing
the costs of the intervention. Prior research has proven the
effectivity and efficiency of novel treatment solutions that
incorporate telemonitoring and virtual coaching [11]. To our
knowledge, however, no clinical trial has been conducted with
a multimodal intervention based on the concept of Living well
with COPD that is delivered remotely.
To fill this gap in research, we, a consortium between IBM
Research, docdok.health, the University Hospital Zurich, and
the Swiss Federal Institute of Technology developed a
comprehensive telemonitoring and hybrid virtual coaching
solution called CAir, which is based on the Living well with
COPD program, and will investigate its effects on the HRQOL
in patients with COPD.
Hypotheses
The primary outcome of this study is the assessment of patients’
change in HRQOL, which we will evaluate with the St. George
Respiratory Questionnaire (SGRQ) [12], a survey specifically
designed for patients with chronic airflow limitations. A minimal
clinically important difference of an average SGRQ score
decrease of 4 units is associated with a slightly effective
intervention, 8 units with a moderately effective intervention,
and 12 units with a very effective intervention in patients with
COPD [13].
Against this backdrop and considering the comprehensiveness
of CAir, the hypotheses of this study are as follows:
1. More than 80% of the intervention group will have a
≥4-point change in SGRQ.
2. More than 40% of the intervention group will have a
≥8-point change in SGRQ.
3. More than 20% of the intervention group will have a
≥12-point change in SGRQ.
4. Approximately 10% of the control group will have a
≥4-point change in SGRQ.
We formulated the fourth hypothesis based on the Hawthorne
effect [14], which states that individuals change their behaviour
when they know they are being observed. This assumption is
further supported by several studies in which the mean HRQOL
within the control group also increased in a clinically relevant
manner without any intervention [15].
Methods
We will perform a monocentric, assessor-blind, two-arm
(intervention/control) randomized controlled trial. The allocation
ratio between the intervention and control group will be 2:1.
Bias will be minimized through randomization, allocation
concealment, assessor blinding, and statistical adjustment or
subgrouping during the analysis. The study is expected to have
an overall duration of 18 months (first patient in, last patient
out). The length of study per patient will be 12 weeks. The
recruitment period will last several months.
Participants
Eligibility Criteria
Participants will be recruited from the Swiss population affected
by COPD. Inclusion and exclusion criteria are outlined in
Textbox 1.
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Textbox 1. Inclusion and exclusion criteria and re-screening for the CAir study.
Inclusion criteria:
• Provision of written informed consent
• Age≥40 years
• Ability to speak German fluently
• Diagnosis of chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
Exclusion criteria:
• Physical or intellectual impairment precluding informed consent or protocol adherence
• Acute or recent (within the last 6 weeks) exacerbation of chronic obstructive pulmonary disease
• Attending a pulmonary rehabilitation program within the last 3 months
• Ongoing pregnancy
Re-screening
• In case of an exacerbation less than 6 weeks prior to the study or completing a pulmonary rehabilitation less than 3 months previous to the study,
patients can be included with a delay to ensure eligibility
Recruitment, Screening, and Informed Consent
Procedure
Participants will be recruited directly from the outpatient clinic
of the Department of Pulmonology of the University Hospital
Zurich by a physician or study coordinator involved in the care,
and indirectly by screening the hospital’s patient database for
the eligibility and ineligibility criteria (Textbox 1). In case
patients meet the criteria, they will be contacted by a letter of
enquiry that contains a study information sheet and a prestamped
reply envelope. Those indicating interest in taking part in the
study will be contacted by phone. In addition, cooperating
pulmonary clinics and primary care physicians will equally
screen their databases for patients fulfilling the main inclusion
criteria (ie, diagnosis of COPD and age ≥40 years) and will send
them study participation requests. Interested patients will then
independently contact the study team of the University Hospital
Zurich, which will evaluate the remaining inclusion and
exclusion criteria.
We will not offer any material compensation for participating
in this study. Potential participants will be informed about the
scientific benefit of their participation; however, no other
incentives will be offered.
All patients will be required to provide written informed consent
before starting the trial. In that context, investigators will educate
each participant about the nature of the study, its purpose,
procedures involved, expected duration, potential risks and
benefits, and any possible discomfort. Patients will also be
informed that their participation is strictly voluntary and that
they can withdraw from the study at any time without stating
any reason. They will also be informed that withdrawing from
the study will not affect subsequent medical assistance and
treatment. The participants will be further advised that their
medical records may be examined by authorized individuals
other than their treating physician. Participants will be given
sufficient time to reflect extensively on their participation.
The consent form will be signed and dated by the investigator
or designee immediately following the signature of the
participant. The consent form will be retained as part of the
study records. A signed copy will be provided to each study
participant.
Sample Size
Sample size calculations used a power of 80% and a two-sided
significance level of 0.05. To increase usability reporting and
account for possible dropouts, we decided to use a 2:1
(intervention:randomization) ratio and doubled the result of the
sample size calculation. The sample size calculation yielded a
total of 42 patients (28 intervention, 14 control). This sample
size will result in an effect size of 0.9 to detect a clinically
relevant between-group difference in the SGRQ.
Technological Study Setup
Considering proper charging and data transfer, the daily usage
of multiple connected devices can be very demanding for some
individuals. Thus, a selection of sensors was combined into the
CAir Desk to improve usability and compliance. The CAir Desk
can be placed next to the patient's bed and allows charging of
all devices with a single power plug (Figure 1).
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Figure 1. CAir Desk with sensors.
The smartphone serves as not only the user interface to enter
questionnaires and access the symptom history through the
docdok app, but also a data transfer hub from the devices to the
CAir database in the IBM Cloud. Patient symptoms and the
environment are tracked through a home spirometer (Air Next
Spirometer, NuvoAir) to capture lung function (forced
expiratory volume in 1 second/forced vital capacity), a wearable
physical activty tracker (Charge 3, Fitbit Inc) to report vital
signs as well as the number of daily steps as a proxy for physical
activity, and the microphone and camera of the smartphone
(A320, 2017, Samsung Group) to acquire nocturnal cough
intensity and the color of patients’ sputum as an indicator for
bacterial content. Finally, the air quality and smoking behavior
in the bedroom is monitored (Foobot, Airboxlab, Esch sur
Alzette) through modalities like temperature and humidity,
particulate matters, and volatile organic compounds in the air.
This integrated approach allows the initialization, setup, and
testing of all devices before the handover to the patient and thus
mitigates any installations and related technical issues from the
patient. To assure the on-state of the Bluetooth and WiFi hotspot
channel of the smartphone, a macro app (MacroDroid, developed
by ArloSoft) was enabled, triggering switch-on events after a
system restart or power connection events. All unnecessary apps
on the phone are suppressed by an app-blocking app (Confidant,
developed by Confidant Inc.).
The CAir backend performs data collection and storage
management by microservices running in the cloud (Figure 2).
Patient information, device allocations, and interactions are
stored in a relational database, compared to a schema-free
JavaScript Object Notation object store (ElasticSearch, Lucene
library) for the raw sensor data. Data are collected from the
sensors in one of two ways: (1) through the third party cloud
of the sensor providers and then downloaded to the CAir cloud
or (2) directly from the CAir app to the CAir cloud. Patient
details and daily summaries can be accessed by the study team
through a web-based docdok.health physician dashboard.
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Figure 2. CAir data management architecture and data flow.
Further, a CAir chatbot backend was implemented using IBM
cloud functions and the IBM Watson Assistant for just-in-time
interactions with the patients through a chatbot frontend
provided by docdok.health. Timed triggers initiate daily
conversations, such as informative sessions, physical exercises,
or patient feedback through the docdok app. Further, these
functions scan the databases for daily activities, degrading scores
of the COPD assessment test, or nonadherence to the study
protocol, notifying the study team through the docdok dashboard
for health care professionals to intervene. The content and logic
of the chatbot conversations are implemented using the IBM
Watson Assistant, which is queried by the cloud functions to




Participants randomized to the control group will receive usual
care (ie, physician visits every 3-6 months and therapy according
to respective treatment guidelines) and a CAir Desk for 12
weeks. The CAir Desk will assess daily symptom burden,
physical activity, and spirometry data. Patients will receive daily
COPD assessment questionnaires through the smartphone and
will be required to wear the physical activity monitor during
the day and night. The threshold for sufficient physical activity
and spirometry data requires measurements on at least 3 days
per week. In contrast to the intervention group, participants will
not receive any feedback or scores of the telemonitoring efforts,
such as the daily reported COPD assessment test and daily
physical activity, nor will they receive any virtual coaching.
In case of any worsening symptoms, no alert message will be
generated. Patients will have to contact their general physician
or pulmonologist individually and independently. No
modification of any treatment will be made by the study team
during the study.
Intervention Group
Participants randomized to the intervention group will receive
a CAir Desk and a hybrid digital coaching intervention for 12
weeks.
The first week will serve to measure baseline levels of daily
physical activity. Starting in the second week of the study,
participants will receive individualized feedback on their daily
physical activity through the CAir chatbot app. We calibrated
the daily target step count to be 15% above the patient's baseline
value. The telemonitoring solution will send alerts to the study
team in case the patient’s daily COPD assessment test score
drops by 2 or more points in 2 consecutive days. A 2-point drop
is considered the minimum clinically relevant difference [16].
In those cases, a physician will contact patients by phone to
discuss if any further actions have to be taken to treat or prevent
a possible exacerbation (ie, taking medication or planning a
physician visit).
In addition, the CAir chatbot will provide virtual coaching to
the patients of the intervention group: (1) a self-paced
educational component about living with COPD based on the
Living well with COPD program [9] that aims to foster patient
empowerment through engagement and awareness and (2) a
dynamic motivational interviewing component to increase
physical activity, one of the most critical behaviours that are of
prognostic relevance. The chatbot is rule-based with predefined
answer options only and does not have any anthropomorphic
visual cues. We used IBM Watson as a development tool. Data
gathered via the CAir Desk autonomously feeds into the chatbot
interaction without time lag as a digital trigger, that is, the script
of the chatbot automatically adapts if the patient has not
achieved the required target step count.
During 2 time periods of the intervention, a COPD expert will
grant optional additional support via chat, making the entire
intervention a hybrid solution (involving the chatbot and human
health care provider), which has been described in other studies
[17].
The overall study is depicted in Figure 3.
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Figure 3. CAir Study overview.
Outcomes
Primary Outcome
As a primary outcome, we will measure the delta in HRQOL,
which we will assess with the SGRQ [12] from baseline to week
12 (the end of the intervention). The SGRQ is a well-established
self-administered questionnaire that is valid, reliable, and
responsive for the population affected by COPD. Participants
will not have access to their completed questionnaires and
scoring to reduce potential bias.
Secondary Outcomes
To evaluate the effectiveness of CAir holistically, we will
include a set of secondary endpoints. Changes in the functional
exercise capacity will be analyzed using the 1-minute
sit-to-stand test and the 6-minute walk test, which have been
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demonstrated to be reliable, valid, and responsive in assessing
functional exercise capacity in patients with COPD [18,19].
The 1-minute sit-to-stand test is performed using a standardized
protocol [18,20]. A conventional chair without armrest and a
seat height of 46 cm will be used. The patient will be instructed
to stand up and sit down as often as possible at a self-chosen
speed over 1 minute. The number of sit-stand repetitions will
be counted by the assessor. Verbal encouragement will not be
provided during the test, but the patient will be told after 45
seconds that another 15 seconds are left until the test is over.
Patients will be allowed to stop at any time during the test. When
standing up, the patient’s legs have to be completely straight,
and when sitting down, the bottom has to have clear contact
with the chair. The patients will be told to place their hands at
the hips and will not be allowed to use their hands or arms to
assist movement. Measurements of heart rate, peripheral
capillary oxygen saturation, and modified Borg scale of
perceived exertion [21] will be performed before and after the
1-minute sit-to-stand test using the same assessment tools as
for the 6-minute walk test.
The 6-minute walk test will be performed according to technical
standards of the American Thoracic Society/European
Respiratory Society [22]. The test will be carried out on a
marked circular 75-m hallway and patients will be told to walk
as far as possible within the 6 minutes. The walking distance
(in meters) will be registered at the end of the test. Patients will
be allowed to take breaks during the test if necessary; time
recording, however, will not be interrupted. Standardized
instructions and phrases of encouragement will be given each
minute. Oxygen supplementation will be installed if required,
and the patients will carry their oxygen device during the test.
Before and after the test, heart rate and oxygen saturation will
be measured with a pulse oximeter (Masimo Rad-5v, Masimo
Corp) connected to the index finger. Ratings of perceived
exertion and dyspnea will be evaluated using a 0-10 modified
Borg scale.
The COPD Assessment Test [23], a validated patient-completed
questionnaire, will be provided daily on the smartphone to
capture the gradual change in symptom burden.
Changes in spirometry will be measured daily with the forced
expiratory volume in 1 second and forced vital capacity. Lung
function testing will be performed according to the guidelines
of the European Respiratory Association and the American
Thoracic Society [24].
Total change in daily physical activity will be expressed as the
number of steps per day. This will be assessed using a physical
activity tracker. The device will be worn as a wrist band.
Wearing times will be throughout day and night. During times
of lower activity (eg, while having dinner, reading, or watching
TV), the device may be placed on the CAir Desk, recharging
its battery and synchronizing the data.
The number of recorded coughs per night will be used as a proxy
for the total change in nightly cough. Compliance with the
COPD medication will be captured daily and compared within
and between the intervention and control group.
Exploratory Endpoints
Exploratory endpoints to support the analysis will also be
considered. We will investigate the usability and limitations of
CAir through specifically designed questionnaires (eg, usability
questionnaire) and structured focus group interviews at the end
of the study. In the case of an exacerbation, we will compare
the data assessed by CAir before and after the event. We will
also analyze air quality by continuously measuring volatile
organic compounds, which are harmful organic chemicals found
in products such as cleaners and in cigarette smoke. Serious
adverse events related to the intervention, such as medical
occurrences that require in-patient hospitalization or
prolongation of existing hospitalization, will be captured as
safety endpoint variables.
A detailed overview of primary, secondary, and exploratory
endpoints, including their measurement frequency, is depicted
in Table 1.
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✓✓St George Respiratory QuestionnaireHealth-related quality of life
Secondary outcome
✓Daily✓COPDa assessment testSymptom burden
✓Daily✓Forced expiratory volume in one secondSpirometry
✓Daily✓Forced vital capacity
✓✓1-minute sit-to-stand testFunctional exercise capacity
✓✓6-minute walk test








Exacerbation and air quality
In case of eventEx ante data
In case of eventEx post data
ContinuouslyVolatile organic compounds
aCOPD: chronic obstructive pulmonary disease.
Statistical Analysis
Statistical analysis will be carried out after completing the data
collection period, which will last around 18 months. We will
not perform any interim analysis. We will use descriptive
statistics to describe group characteristics and perform
independent samples t tests to explore and identify potential
differences at the primary endpoint (HRQOL) between the
intervention and control group. We will compare the differences
in the percentages of SGRQ (≥4 points) improvement between
the control and intervention groups. The statistical analysis will
be performed using the latest version of R (R Core Team 2019)
for Windows. Missing data at the baseline and end of study
visits will be handled through multiple imputation at the analysis
stage. Factors prone to influence endpoints, such as gender, age,
and the Global Initiative for Chronic Obstructive Lung Disease
classification, will be assessed and accounted for in the analysis
and interpretation of the data.
Ethics and Dissemination
The study has received approval by the Ethics Committee of
the Canton of Zurich and was registered in ClinicalTrials.gov
(identifier: NCT04373070).
After the statistical analysis of this study, overall and
subordinate findings will be submitted for publication in
peer-reviewed journals. Dissemination of the results will be
independent of negative or positive findings. The principles of
the American Psychological Association guidelines for
authorship eligibility will be followed.
Results
The development of the CAir Desk and virtual coach is
completed. Recruitment to the trial started in September 2020.
We expect to start data collection by December 2020. This is
5 months behind schedule, which is due to the outbreak of
COVID-19 that heavily impairs patients with COPD. Data
collection is expected to last for approximately 18 months (first
patient in, last patient out), as we follow a multiwave approach.
The length of study per patient will be 12 weeks. The limited
amount of available CAir Desks prevents us from executing a
larger number of interventions simultaneously. We expect to




To our knowledge, this is the first study investigating a
combination of telemonitoring and hybrid virtual coaching in
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patients with COPD. We will investigate the effectiveness,
efficacy, and usability of the proposed intervention and thus
provide evidence to further develop app-based and chatbot-based
disease monitoring and interventions in COPD. The study may
also be extended to other respiratory diseases (eg, cystic fibrosis
and COVID-19) and with an adapted technical setup to other
chronic diseases requiring long-term treatment (eg, diabetes
mellitus type 2 and chronic kidney disease).
Strengths and Limitations
Randomized controlled trials are considered the “gold standard
for evaluating efficacy in clinical research and constitute
evidence for medical treatment” [25]. By adopting such a trial
and ensuring internal as well as external validity, we maximize
the robustness of our study. To make sure that the CAir Desk
will function well with the study population, we extensively
pretested the device in patients with COPD. The technology we
used as part of the CAir Desk is well established and not likely
to malfunction in daily use. A possible limitation is that the
intervention is rather technology-heavy and the study population
includes persons aged 45 years and older. Even though we
pretested the system usability extensively in patients with COPD
from the same population, some participants might feel
overwhelmed and therefore discontinue the study. In addition,
patients may feel overloaded by the daily measurements and
questionnaires to be answered, which could also lead to
dropouts. Another possible limitation is the limited size of the
sample, given the heterogeneity in the population affected by
COPD.
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